MedTrace Logo

Dose-response Study of Exendin-9,39 on Glucose Metabolism

NCT01218633 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2013-01-23

No results posted yet for this study

Summary

Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.

Conditions

  • Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1

Interventions

DRUG

saline infusion

saline infused at 30ml/hour

DRUG

GLP-1-9,36 infusion

infused @ 1.2pmol/kg/min

DRUG

Exendin-9,39 at low dose

infused at 30pmol/kg/min

DRUG

Exendin-9,39 at high dose

infused @ 300pmol/kg/min

Sponsors & Collaborators

  • Adrian Vella

    lead OTHER

Principal Investigators

  • Adrian Vella, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-07-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01218633 on ClinicalTrials.gov